Supply of Recombinant Factor VIII Products for NHS Bleeding Disorder Treatment
Awarded 01 Feb 2018
About
NHS England awarded a national framework agreement to Baxalta Limited, Bayer Plc, Novo Nordisk Limited, Octapharma Limited, and Pfizer Limited for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders.
The framework commenced on 1 February 2018 for a 12-month period until 31 January 2019, with options to extend for up to a further 17 months.
The contract value is AUD 302,000,000.
Similar open tenders12
Other similar contracts12
Unlock the full platform.
7 days free, then £36/GBP per month. Cancel anytime.
What you get
Find
Find health and medical tenders in United Kingdom in one place.
We monitor central, devolved and local government portals in near real time and update the feed as tenders are published, so you check one place instead of many.
Alerts
Open tenders like this contract, sent to you.
Tell us what you are looking for and we email you when a matching tender is published.
Assess
Size up a tender in minutes.
Before you open a single document, get the requirements, a likely value and who you would be up against.
Market
Follow this supplier and get alerts when they win again.
Awarded contracts with the supplier and the value, so you can check prices, spot competitors and find work that is coming back to tender.
Pipeline
Track your bids from interested to won.
Save a tender in one click and move it through each stage as you work on it.
GovBot
Ask a question in plain English.
Find tenders, look up a supplier, or check who won a contract. Just type what you need.
Get started
Get health and medical tenders in United Kingdom by email.
Find the tender, size it up and track the bid, in one place.
7 days free, then £36/GBP per month






